Giant Prolactinomas: Report of 6 Cases and Review of Literature

Mouna Ammar^1, , Faten hadjkacem¹, Manel Akrout¹, Ayman Maalej², Nadia Charfi¹ and Mohamed Abid¹

¹Department of endocrinology, Hedi Chaker Hospital, Sfax, Tunisia

²Department of radiology, Habib Bourguiba Hospital, Sfax, Tunisia

Cite this paper:
Mouna Ammar, Faten hadjkacem, Manel Akrout, Ayman Maalej, Nadia Charfi and Mohamed Abid. Giant Prolactinomas: Report of 6 Cases and Review of Literature. American Journal of Medicine Studies. 2016; 4(1):11-16. doi: 10.12691/ajms-4-1-2

Abstract

Introduction: Giant prolactinomas are rare tumors, representing only 2- 3% of all prolactin (PRL)-secreting tumors. Endocrine symptoms are often present but overlooked for a long period of time. The management of giant prolactinomas remains a major challenge, despite dopamine agonists being the first line of treatment, owing to its efficacy to normalize prolactin levels and reduce tumor volume. Aim of the study: Describe clinical and radiological features, the treatment modalities and outcomes of 6 cases of giant prolactinomas and review of the literature. Methods: Retrospective data collection involving 6 patients diagnosed with giant prolactinoma in the Department of Endocrinology, Hedi Chaker Hospital, Sfax, Tunisia from January 2010 to December 2014. Results: All patients were men between the age of 19 and 65 years. The most common presenting features include headache and visual defects. Proptosis was reported in one patient. Tumor size ranged from 56 to 84 mm and pre-treatment PRL from 1470 to 642387 ng/mL. Endocrine evaluation performed at baseline showed secondary hypogonadism in all patients. Secondary hypothyroidism and adrenal insufficiency were found in one and four patients respectively. IGF-I level was within the normal range for age and gender for all patients. Dopamine agonists served as the primary therapy for all the patients in the present study. Trans-frontal pituitary surgery was performed in one patient with apoplexy and severe neuro-ophthalmic signs. Serum prolactin concentrations and tumor volume significantly decreased following treatment with dopamine agonists. Conclusion: Giant prolactinomas are uncommon and often raising both diagnostic and therapeutic challenges.

Keywords:
dopamine agonist giant prolactinoma pituitary tumor

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Siddiqui A, Chew N & Miszkiel K. Unusual orbital invasion by a giant prolactinoma. British Journal of Radiology 2008 81 259-262.
[2]	Cho EH, Lee SA, Chung JY, Koh EH, Cho YH, Kim JH, Kim CJ, Kim MS. Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma. J Korean Med Sci 2009 24(5) 874-878.
[3]	Shrivastava RK, Arginteanu MS, King WA & Post KD. Giant prolactinomas: clinical management and long-term follow-up. Journal of Neurosurgery 2002 97 299-306.
[4]	Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA &Colosimo C. Giant prolactinomas in men: efficacy of cabergoline treatment. Clinical Endocrinology 2003 58 662-670.
[5]	Moraes AB, Silva CM, Vieira Neto L &Gadelha MR. Giant prolactinomas: the therapeutic approach. Clinical Endocrinology 2013 79 447-456.
[6]	Delgrange E, Raverot G, Bex M, Burman P, Decoudier B, Devuyst F, Feldt-Rasmussen U, Andersen M &Maiter D. Giant prolactinomas in women. European Journal of Endocrinology 2014 170 31-38.
[7]	Schaller B. Gender-related differences in prolactinomas. A clinicopathological study. Neuroendocrinology Letters 2005 26 152-159.
[8]	Maiter D & Delgrange E.The challenges in managing giant prolactinomas. European Journal of Endocrinology 2014 170 213-227.
[9]	Minniti G, Jaffrain-Rea ML, Santoro A, Esposito V, Ferrante L, Delfini R & Cantore G. Giant prolactinomas presenting as skull base tumors. Surgical Neurology 2002 57 99-104.
[10]	Ahmed M & Al-Nozha O. Images in clinical medicine. Large prolactinoma. New England Journal of Medicine 2010 363 177.
[11]	Deepak D, Daousi C, Javadpour M & MacFarlane IA. Macroprolactinomas and epilepsy. Clinical Endocrinology 2007 66 503-507.
[12]	Brisman MH, Fetell MR & Post KD. Reversible dementia due to macroprolactinoma. Case report. Journal of Neurosurgery 1993 79 135-137.
[13]	Scho¨fl C, Scho¨fl-Siegert B, Karstens JH, Bremer M, Lenarz T, Cuarezma JS, Samii M, von zur Mu¨hlen A & Brabant G. Falsely low serum prolactin in two cases of invasive macroprolactinoma. Pituitary 2002 5 261-265.
[14]	Scarone P, Losa M, Mortini P & Giovanelli M. Obstructive hydrocephalus and intracranial hypertension caused by a giant macroprolactinoma. Prompt response to medical treatment. Journal of Neuro-Oncology 2006 76 51-54.
[15]	Alkatari S & Aljohani N. Obstructive hydrocephalus, fifth nerve and hypothalamus involvement: acute presentation of a giant prolactinoma. Clinical Medicine Insights. Case Reports 2012 5 115-118.
[16]	Chattopadhyay A, Bhansali A & Masoodi SR. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men. Pituitary 2005 8 147-154.
[17]	Fleseriu M, Lee M, Pineyro MM, Skugor M, Reddy SK, Siraj ES & Hamrahian AH. Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of ‘hook effect’. Journal of Neuro-Oncology 2006 79 41-43.
[18]	Baldari S, Ferrau` F, Alafaci C, Herberg A, Granata F, Militano V, Salpietro FM, Trimarchi F & Cannavo` S. First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment. Pituitary 2012 15 (Suppl 1) S57-S60.
[19]	Berwaerts J, Verhelst J, Abs R, Appel B & Mahler C. A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature. Journal of Endocrinological Investigation 2000 23 393-398.
[20]	Cackett P, Eunson G, Bath L & Mulvihill A. Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy. Future Oncology 2012 8 1-6.
[21]	Inagawa H, Ishizawa K, Mitsuhashi T, Shimizu M, Adachi J, Nishikawa R, Matsutani M & Hirose T. Giant invasive pituitary adenoma extending into the sphenoid sinus and nasopharynx: report of a case with intraoperative cytologic diagnosis. Acta Cytologica 2005 49 452-456.
[22]	Care RH, Sunkaraneni VS, Theaker J & Harries PG. Rapidly progressing giant invasive prolactinoma. Journal of Laryngology and Otology 2012 126 840-843.
[23]	Sunil B, Reddy A, Bryant N, Young DW & Ashraf AP. Invasive giant prolactinoma presenting as a nasal polyp. Journal of Pediatrics 2013 162-435.
[24]	Grebe SK, Delahunt JW, Feek CM. Treatment of extensively invasive (giant) prolactinomas with bromocriptine. NZ Med J 1992 105 129-131.
[25]	Perani D, Colombo N, Scotti G, Tondon C. Rapid size reduction of giant prolactinoma following medical treatment. J Comp Assist Tomogr 1984 8 131-133.
[26]	Ariel L, Barkan MD, Wiliam F, Chandler MD. Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the “High-dose Hook Effect”: Case report. Neurosurgery 1998 42 913-916.
[27]	Gillam MP et al. Advances in the treatment of prolactinomas. Endocr Rev 2006 27(5) 485-534.
[28]	Wu ZB, Yu CJ, Su ZP, Zhuge QC, Wu JS, Zheng WM. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. J Neurosurg 2006 104(1) 54-61.
[29]	Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, Colosimo C. Giant prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol (Oxf) 2003 58(5) 662-670.
[30]	Shimon I, Benbassat C, Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol 2007 156 225-31.
[31]	Davis JR, Farrell WE, Clayton RN. Pituitary tumours. Reproduction 2001 121(3) 363-71.
[32]	Yang MY, Shen CC & Ho WL. Treatments of multi-invasive giant prolactinoma. Journal of Clinical Neuroscience 2004 11 70-75.